Can the health materials be turned over in the field of neuropathy?

Source: Yaozhi.com/Forest

In recent years, cancer has become the "number one killer" for human health, and the demand for medication has continued to expand. The field of tumor seems to have become a must -have for the research and development layout of major pharmaceutical companies.

However, the field of tumor is also the most intense area in the future. The speed of the iteration of drug updates may be beyond the cognition of many people. Do you continue to increase investment in popular areas or focus on your own advantages? This is a question worth thinking about.

A few days ago, Wei Materials announced the resolution of its global architecture adjustment, and turned its global R & D (R & D) organization from the previous business group structure reform to a new R & D organization DHBL (Deep Human Biology Learning).

A few days later, Wei Materials decided to permanently close the H3 Biomedicine of the oncology department, and the number of layoffs is expected to be 88, of which 79 will be abolished by September 15. According to Fierebiotech, the work of the tumor department will continue in the DHBL department.

4 products have entered the clinic

Guardian still decides to close H3 biomedicine

H3 Biomedicine was established in 2010. It focuses on the use of its integrated data science, human biology and precision chemical discovery engines to discover and develop precision tumor treatment methods.

Four products have entered the clinical development stage. The main candidate H3B-6545 is a small molecular selective estrogen receptor covalent antagonist, which is used to treat patients with breast cancer with mutations suffering from estrogen receptors. In addition, there are several other products for liver cancer, bladder cancer, physical tumors and hemoma.

H3 biometine product pipeline

Source: h3 biometine official website

In August last year, H3 also hired Ross Pettit, a senior vice president of Global Development and Operation of the Global Development and Operation of Baiji, as the vice president of business operations. In just a few months, the guards have decided to close H3.

On July 15, 2022, Wei Materials announced the new organizational structure DHBL (Deep Human Biology Learning, Human Biological Deep Learning), which is scheduled to start on October 1, 2022. Prior to this, the neurological business group, tumor business group, drug development center, and HHC data creation center will be dissolved. The closure of H3 biometricine is also part of the huge plan.

According to the discovery and development of DHBL drugs, the disease will be regarded as a continuity of the disease, and the genetic information, pathophysiological information and clinical information related to the root cause of the disease will be comprehensively analyzed. The health material will use more in -depth human biological learning, based on the patient's biomarkers and medical images, and use other technologies such as AI to find the next -generation drugs more efficiently and innovatively.

On the other hand, Wei Materials stated that Alzheimer's disease and related brain disease correction therapy (DMT) related R & D, regulatory, medical, value, access, marketing and alliance management functions, of which the next generation of Alzheimer LecaneMab is the most important item.

Fully bet on the field of neuropathy

Can the guards come back?

The Headquarters Headquarters is located in Tokyo, Japan, and is one of the five major pharmaceutical giants in Japan.

As early as 1996, Wei Materials launched the classic therapy drug Hydrochloride Qiqi of Alzheimer's disease, and combined with Pfizer and Johnson & Johnson to make the medicine into a "explosive product". Over the past few decades, Wei Qi has bet on CNS drug research and development.

According to the 2021 fiscal annual report, two of the four main products with the highest sales are the field of neuropathy -Fycompa and Dayvigo, with sales of 31.9 billion yen (about 1.57 billion yuan) and 16.4 billion yen, respectively. (About 809 million yuan).

Health Materials Commercial Listing Products

Source: Wei Material

More than 20 years after the launch of Domani, Wei was launched last year with ADuhelm for the treatment of early Alzheimer's disease. However, this time the guard material is not so good, and ADUHELM's approval is controversial and did not achieve expected sales.

However, the storm of Aduhelm did not affect the research and development of LECANEMAB, another Alzheimer's therapy for Bo Jian and Wei Materials.

A few days ago, Wei Materials and Bo Jian announced that the FDA in the United States has granted its Alzheimer's disease priority review of Lecanemab, and the PDUFA date is January 6, 2023. The medicine was determined by the FDA breakthrough therapy last June and was highly hoped by the guards.

LECANEMAB is similar to ADuhelm. It is a humanized monoclonal antibody that treats Alzheimer's disease (AD). LecaneMAB selectively bind to neutralize and eliminate soluble, toxic Aβ agglomerations (original fibers), which are considered to accelerate the nervous system degeneration process of accelerated AD. Therefore, LECANEMAB may affect the pathological mechanism of the disease and delay the progress of the disease.

LecaneMab's biological product license application is based on the clinical, biomarkers and safety data of LECANEMAB in Phase IIB clinical trials in conceptual verification IIB, and unrelated blindness data of Phase III clinical trials in Phase III. Phase IIB clinical trial data shows that LECANEMAB reduces the level of brain starch protein plaques. After 18 months of treatment, LECANEMAB (10mg/kg, once every two weeks) reduced the level of brain amyloid -like protein by 0.306SUVR (baseline value of 1.37). More than 80%of participants meet the negative standards of amyloid protein when the visual evaluation scanning image is reached. At the same time, the level of decreased starch protein is correlated with the slowing rate of a number of cognitive scores. In addition, the clinical clinical clinical clinical clinical of the early AD is expected to obtain the main clinical ending data in this fall. In addition to LECANEMAB, there are also many products in the field of neuropathy.

Lemborexant (Dayvigo) is an Orexin receptor antagonist independently developed by the guard. The two studies for adult patients with insomnia patients 3 (Sunrise 2 and Sunrise 1) The results show that compared with placebo, in terms of subjective and objective evaluations, LEMBOREXANT shows significant statistics in sleep and sleep maintenance Sexual advantages. Therefore, DAYVIGO was approved by the US FDA in 2019, becoming the first insomnia drug with 12 months of treatment of safety data and 6 months of sleep and sleep maintenance data.

Fycompa is a new type of antiepileptic drugs developed by Wei Materials. It is a high -selective, non -competitive AMPA receptor antagonist. At present, Piraona has been approved to be listed in more than 70 countries and regions, including Japan, the United States, China, and other countries in Europe and Asia. Auxiliary treatment of secondary comprehensive epileptic seizures). In addition, the indications approved by Pena Panani in the world include: the primary systemic systemic adeptics-clonic therapy, single drug treatment and auxiliary therapy of epilepsy in the age of 12 and above Seizure seizures (accompanied by non -secondary comprehensive epileptic seizures). The sanitary material also conducts a phase III clinical research (research 338) worldwide, which is intended to take the medicine for the treatment of epileptic seizures related to Lennox-Gastaut syndrome. In addition, the development of sanitary materials injection preparations is also underway.

Lorcaserin (Belviq) is a selective serotonin 5-hydroxylin 2C (5-HT2C) receptor agonist. It was originally developed by American Pharmaceutical Company ARENA, and was approved by FDA in 2012 for adult obesity or overweight patients who were approved by the FDA for BMI ≥ 27kg/m2. Later Commercial rights. However, in 2020, due to the increase in the incidence of cancer in clinical trials, the FDA demanded that Lorcaserin is suspended. However, at the same time, Lorcaseerin made progress in treating chronic severe epilepsy (DRAVET syndrome) for children. At present, Lorcaserin's three -phase study on Dravet syndrome is underway. The FDA has granted it for orphan drug qualifications for the indications.

Conclusion

In recent years, the emergence of new technologies such as immunotherapy has made anti -tumor treatment greatly progress, and various types of new drugs have competed. However, issues such as the risk of anti -tumor new drugs and fierce competition cannot be ignored.

At this year's ASCO conference, Pfizer’s world's first CDK4/6 inhibitor clinical data of CDK4/6 inhibitors is not ideal. Essence Roche Tigit's defeat made a number of new Tigit targets a new medicine. The ENHERTU of the first and third Republican Astron may deeply affect the treatment of breast cancer because of its excellent clinical data. At the same time, the drugs designed by the following generation of ADC drugs for "templates" may cause a very fatal blow.

The field of tumors has long been competitive in the Red Sea, with high risks and uncertain life cycle. It may no longer be the best choice for "endogenous growth" companies.

As for some slow updates, such as Alzheimer's Circles, in recent years, in addition to the ADUHELM of the guards and the nine periods of the country, the new drugs that have been named and recognized by the market are basically extinct. With deep accumulation in the field of neurological diseases, Wei Materials may really break the deadlock of Alzheimer's disease and achieve new glory.

Reference source:

1.https://www.fiercebiotech.com/biotech/exClusive-eisais- OnCology-rd-wing-H3- Biomedicine-Closing-GOOD

2. Wealth Materials Official Website

- END -